In the future, we also aim to establish whether the magnitude of VSI is an early biomarker of AD pathology, by examining associations of VSI with Aβ accumulation, plasma‐based total and phosphorylated Tau, neurofilament (NfL), APOE, and multimodal neuroimaging measures of Neurodegeneration. The gene discussed is MAPT; the disease is Alzheimer disease.